SI
SI
discoversearch

 Biotech / Medical | VRAL - Viral Genetics, Inc.


Previous 10 | Next 10 
To: jmhollen who wrote (11)2/4/2011 11:51:03 AM
From: jmhollen
   of 35
 
Per a conversation with the Transfer Agent this morning,
O/S = 636MM+/-
A/S = 750MM (only 1/2 that shown on OTCMarkets.com)

A friend of mine waited almost 20 minutes yesterday to get a "Market Order" filled. This would tend to show things are getting tight.
.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: jmhollen who wrote (12)2/4/2011 6:48:56 PM
From: jmhollen
   of 35
 
Correction: I subsequently cross-checked with the HQ who gave me the current status:
A/S = 1.5B shares.

The other information on OTCMarkets.com is as shown.
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen2/9/2011 3:53:17 AM
   of 35
 
VRAL DD:

patft.uspto.gov

appft.uspto.gov

v3.espacenet.com
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen2/11/2011 3:30:15 PM
   of 35
 
More from Biotech Stock Review:
Quote:
Today we (Biotech Stock Review) issued a press release announcing that are updating coverage on Viral Genetics (VRAL) as well as to note that we will be issuing a detailed research report before the quarter is out (a more reasonable time table).
...
What was anticipated was:

1. Appearance on the Wide World of Stocks in December.
2. Initiation of Clinical Trials at Scott & White Cancer Treatment Center in Temple, Texas.
3. Full report issued by the Biotech Stock Review in December.
4. Full report issued by Research 2.0 in January.
5. Report on progress of recently formed VG Energy, a majority owned subsidiary.

What actually happened was (December and until last week):

1. Appearance on the Wide World of Stocks in December.
2. Funding of Clinical Trials at Scott & White Cancer Treatment Center in Temple, Texas (a huge surprise).
3. Full report issued by the Biotech Stock Review in December (okay make that late February, early March)
4. Full report issued by Zacks with a $0.15 price target.
5. Full report issued by Research 2.0 with varying scenario price targets ranging from $0.43 to $3.00.
6. Four mentions in Biotech and Health Care News.
7. Detailed coverage of VG Energy in Energy Boom magazine.
8. Settlement of a lawsuit and subsequent reacquiring of their South African to HIV/AIDS technology rights.
9. A wonderfully detailed shareholder letter from management
10. And finally a gradually increasing share price (up 53%) which results in favorable technical readings.
...
So we thought, "like ourselves, probably everyone else has forgotten all of the amazing (and enlightening) amount of information buried in that single press release issued nearly four months ago -- so lets just "cut-n-paste," and re-release it in "report" format and use a bold font (an uncommon practice in press releases) what we consider was jaw dropping, of which there was plenty.

You can find the "update" here: www.biotechstockreview.com biotechstockreview.ning.com
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen2/11/2011 8:33:02 PM
   of 35
 
Some interesting thoughts taken from Yahoo:

VG ENERGY will License their Technology with SOLAZYME Soon. To many DOTS, and I believe HINTS

First WATCH VIDEO of SOLAZYME in this LINK----The many faces of algae
zdnet.com

Remember these Names
SOLAZYME
RICHARD BRANSON
CHEVRON
HARRIS & HARRIS (TINY)
JOHN SHEEHAN
NREL (National Renewable Energy Laboratory)
RESEARCH 2.0
MARSHALL C PHELPS
VIRAL GENETICS/VG ENERGY
-------------------------------------------------

Richard Branson, Chevron and Harris & Harris invest in SOLAZYME

Richard Branson introduced John Sheehan to VIRAL GENETICS

John Sheehan worked for NREL (National Renewable Energy Laboratory)

Chevron PARTNERS with NREL (National Renewable Energy Laboratory)
nrel.gov.
Chevron and NREL to Collaborate on Research to Produce Transportation Fuels using Algae

Research 2.0 put out a Report on Harris & Harris and Viral Genetics within a month
----------------------------------------------------- ---
And all this below is from SHAREHOLDER LETTER

We have recruited John Sheehan, a renowned algae biofuel expert, to assist us in growing VG Energy. He is also assisting in introducing potential industry, public and academic partners to the technology. (Remember JOHN SHEEHAN worked for NREL and CHEVRON invests in SOLAZYME and Partners with NREL)
..................................................... ...

We have yet to finalize which of the MDT compounds are optimal in creating this lipid trigger effect in algae and are working to develop a product that can be commercialized from this pilotscale technology.(In my opinion, they are working with SOLAZYMES Modified Algae Strains.)
futurepundit.com.

Solazyme Algae Biodiesel

The company uses different strains of algae to produce different types of oil. Some algae produce triglycerides such as those produced by soybeans and other oil-rich crops. Others produce a mix of hydrocarbons similar to light crude petroleum.
..................................................... ......
It is possible we will license the technology to one or more partners rather than manufacture and market a product ourselves.
(In my opinion they LICENSE to one ALGAE COMPANY and that is SOLAZYME. Remember CARGILL is not an ALGAE COMPANY)
..................................................... .........
We are actively pursuing industry partners in the food,
chemical and energy sectors. Marshall C. Phelps Jr., a member of our advisory board and former head of intellectual property for Microsoft, will be instrumental in this licensing process. (This is where CARGIIL, MONSANTO, DUPONT or other Companies come in)


messages.finance.yahoo.com
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen2/15/2011 2:30:18 PM
   of 35
 
Viral Genetics' Researcher and Advisor Set to Share Award

Time for Lyme Will Honor Dr. M. Karen Newell Rogers and Mr. Richard Gerstner

SAN MARINO, Calif., Feb. 15, 2011 /PRNewswire/ -- Viral Genetics, Inc. (Pink Sheets: VRAL) announced today that lead researcher Dr. M. Karen Newell Rogers and Advisor Mr. Richard Gerstner will receive the Lauren F. Brooks Hope Award, presented by Time for Lyme, Inc. The award presentation is set for the Illusions of Lyme Gala, April 2, 2011, in Stamford, CT. Dr. Newell Rogers is being recognized for her research on Targeted Peptide treatment for Lyme Disease at the University of Colorado at Colorado Springs and Texas A&M University. Mr. Gerstner helped Dr. Newell Rogers to initiate research on a treatment for the disease and has supported her research with funding.

"We are very proud of Dr. Newell Rogers' work and appreciative of the support that Mr. Gerstner has provided," said Viral Genetics' CEO, Haig Keledjian. "This award is a confirmation that Dr. Newell Rogers' research into a treatment for Lyme Disease is showing results."

"I would like to personally thank Mr. Gerstner for his original gift," added Monica Ord, Viral Genetics' Senior Vice President for Corporate Development and Communications. "Since that day, and with the steadfast support of Tyme for Lyme, Dr. Newell Rogers has uncovered not only a promising treatment but new information about this disease that is invaluable. We have never had such a willingness of immediate support in any other disease as with the Lyme community. We applaud you."

Dr. Newell Rogers and Viral Genetics are now completing the development of a molecule for the treatment of Lyme disease. This molecule is comparable to the Company's APi1177 Targeted Peptide molecule being studied for HIV/AIDS, which appears to rely on a similar underlying mechanism to assist in the control of chronic inflammation believed to be responsible for certain symptoms of Lyme Disease. Preliminary animal studies of this compound showed positive results in decreasing levels of inflammation in Borrelia infection in animals. Viral Genetics' goal is to initiate review of this drug candidate by the United States Food and Drug Administration through a pre-IND filing in 2011. Dr. Newell Rogers' research has been funded, in part, by grants from Time for Lyme, Inc., Mr. Richard Gerstner, and funding from Turn the Corner Foundation.

M. Karen Newell Rogers, Ph.D., is currently the Raleigh R. White Jr. Endowed Professor of Surgical Research at Scott and White Hospital's Department of Surgery, affiliated with Texas A&M University Health Science Center's College of Medicine, located in Temple, Texas. She was previously at the University of Colorado at Colorado Springs, where she began her research into Lyme Disease.

Richard T. Gerstner serves on the Advisory Board of Viral Genetics and is also on the Advisory Committee to Columbia University's Lyme and Tick Borne Diseases Research Center. He has served in executive management in numerous technology companies, including IBM and Telular Corporation.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy (www.vgenergy.net) is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at www.viralgenetics.com

About Time for Lyme

Time For Lyme, Inc. (TFL), formerly The Greenwich Lyme Disease Task Force, is a 501(c)(3), all volunteer, nonprofit organization, and an affiliate of the national Lyme Disease Association (LDA). The organization promotes education about tick-borne illness, including detection, prevention, and advocacy for students and families. Online at www.timeforlyme.org.

www.viralgenetics.com
Contact: Haig Keledjian, Viral Genetics
T: (626) 334-5310
info@viralgenetics.com

prnewswire.com
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen3/8/2011 2:10:58 PM
   of 35
 
Updates:
vgenergy.net
energyboom.com
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen3/9/2011 9:14:49 AM
   of 35
 
VRAL press release
March 9, 2011, 8:07 a.m. EST
VG Energy Report is Featured on EnergyBoom.com

SAN MARINO, Calif., March 9, 2011 /PRNewswire via COMTEX/ -- A new report from VG Energy, a subsidiary of Viral Genetics, Inc. (pinksheets:VRAL), is now featured in an article at EnergyBoom.com (link: energyboom.com ). The EnergyBoom.com piece is entitled "Algal Fuel: VG Energy Study Shows Price Parity Possible With Conventional Oil." The original report was undertaken by biofuels expert John Sheehan, an advisor to Viral Genetics and VG Energy, and is available for download at: vgenergy.net.

"The work being undertaken by VG Energy is showing great promise as a viable and cost effective alternative energy source," said Viral Genetics' CEO, Haig Keledjian. "This report by Mr. Sheehan helps to point the way forward for us, and the coverage from EnergyBoom.com indicates that we are making progress and garnering attention from industry. Our next steps are focused on moving from the laboratory to a production setting."

Mr. Sheehan's report indicates that VG Energy's proprietary technology has the potential to create algal biofuel at prices that are competitive with current prices for crude oil. The process that VG Energy and its lead researcher, Dr. M. Karen Newell Rogers, are using could potentially lower the cost for algal oil production by significant amounts, making it comparable with conventional oil. This process results in increased lipid production in the algae cells as well as increasing the ability to recycle these cells. The report models several different production techniques currently in use with their productivity enhanced by use of VG Energy's compounds through increased lipid production and recyclability, showing a range of prices at which algae oil can be produced. VG Energy is planning studies to demonstrate these yields in practice. Mr. Sheehan is currently the Biofuels Coordinator in the Institute on the Environment at the University of Minnesota, and was previously a project manager at the National Renewable Energy Laboratory in Golden, CO.

The process that VG Energy uses to boost algal oil production is a direct result of work undertaken by Dr. Newell Rogers for cancer treatment. This process, called Metabolic Disruption Technology (MDT), is meant to disrupt cancer cells' ability to burn fat reserves, making them more susceptible to traditional treatments. The same technology appears to also act as a long sought lipid trigger to cause algae cells to store increased fat, making them more productive as an energy source. When the process was applied to algae cells in the lab, extractable lipid, or fat, production was increased by a minimum of 300%. Additionally, the process enables the cells to release fats outside the cell walls, making much of the algae recyclable. The combination of increased lipid production and recyclability appears to make algae economical as a source for a potential biofuel. Dr. Newell Rogers, the Raleigh R. White, Jr. Endowed Professor of Surgical Research at Texas A&M Health Sciences Center and Scott and White Hospital in Temple, Texas, is continuing her research into biofuel technology.

About VG Energy

VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc., a biotechnology company researching new treatments and methods of detection for diseases including cancer, HIV/AIDS and others. Using its Metabolic Disruption Technology ("MDT"), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including bio-fuel and vegetable oils. VG Energy Inc. holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Importantly, these pivotal discoveries promise to allow the biofuel industry to overcome its major obstacle in the area of production efficiency: namely an increase in production yields leading to feasible economic returns on investment allowing renewable biodiesel to be competitive with fossil fuels. For more information please visit jttp://www.vgenergy.net

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy (www.vgenergy.net) is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at viralgenetics.com

Contact: Haig Keledjian, Viral Genetics
info@viralgenetics.com
viralgenetics.com
T: (626) 334-5310
.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: jmhollen who wrote (19)3/9/2011 10:38:56 AM
From: jmhollen
   of 35
 
VRAL
Last
0.0475
+0.0046
(+10.72%)
Bid
0.047
Ask
0.0475
Low
0.043
High
0.0475
Last Trade Time
10:34
Volume
1.09 m
.

Share Recommend | Keep | Reply | Mark as Last Read


From: jmhollen3/9/2011 10:57:51 AM
   of 35
 
Biofuels, Finance
Algal Fuel: VG Energy Study Shows Price Parity Possible with Conventional Oil
By Mitchell Anderson on March 7, 2011

Proprietary technology owned by VG Energy could create algal biofuel at costs competitive with current prices for conventional crude according to a report released by the company this week.

The study was authored by John Sheehan, former project manager at the National Renewable Energy Laboratory and currently the Biofuels Coordinator in the Institute on the Environment at the University of Minnesota. Sheehan also serves on the technical advisory board of VG Energy, a majority owned subsidiary of biotech start-up Viral Genetics (VRAL).

His projections are based on existing industrial processes and early lab results from VG Energy that indicate algae-derived diesel and jet fuel substitutes could be produced at prices competitive with conventional oil at $94 per barrel. This potential price breakthrough comes as world oil prices are spiking well beyond $100 and conventional producers are intimating that world supplies will be squeezed for the foreseeable future.

According to the study:

The introduction of VG Energy’s additives offers the ability to knock down the cost of algal oil production by almost a factor of ten as a result of productivity improvements. If oil secretion currently observed in the lab can be fully demonstrated in larger scale growth systems, there is a potential for further decreasing costs by another factor of roughly two. These represent dramatic changes in the economics of algae technology, and are truly game-changing. A lot of work remains to be done to establish the robustness of the VG Energy’s lab results, but these preliminary economic analyses show that the promise of the technology warrants further investment and investigation.

The long sought after technique to boost algae oil production has an unlikely origin. Viral Genetics researcher Dr. Karen Newell has been developing novel techniques to disrupt tumor metabolism to prevent them from burning fat reserves, making them more susceptible to chemotherapy and radiation.

This same metabolic switch appears to be the elusive lipid trigger that algal biofuel researchers have been seeking since the 1990’s that forces algae to store energy as fat rather than carbohydrates or protein.

When these trace chemical amendments developed by Viral Genetics to fight cancer were added to algae cultures in the lab, they were found to increase extractable lipid production by more than 300%.

“What they have stumbled on indirectly through a fairly unrelated field of research is the possibility that you really can turn on lipid production in algae,” said Sheehan. “For the last five years of the research at the National Renewable Energy Lab, we were entirely focused on exactly this question.”

Algae is attractive for biofuels due to their ability to grow much more quickly than terrestrial crops because they are very simple organisms. The problem is that algae tend to only want to produce the oil when they are stressed or believe they are in a scarce environment.

According to Sheehan, “algal biofuel researchers have been looking for the so-called ‘lipid trigger’ for over a decade. Our goal was to find a way to promote storing of organic carbon in algae in the form of oil, and that is what Karen Newell has appeared to have stumbled on.”

VG Energy’s techniques also cause algae to release fats outside of their tough cell walls creating the potential to recycle algal biomass without destructively extracting the oil. Sheehan feels that a 75% biomass recycle rate is possible, contributing to greatly reduced production cost projections.

Along with the enormous potential market to create economic biofuels, VG Energy’s technique could also create high value nutritional oils such as omega 3 fats at approximately one quarter the price of conventional sources. This market, while far smaller than transportation fuels, is still worth about $1.4 billion annually and growing at 10% per year.

Sheehan, who has been a leading expert in this algal biofuel research for more than fifteen years says that he is “cautiously excited” about the potential price breakthrough, but stresses that much must happen before you can economically fill up your tank with fuel refined from algae.

“VG Energy has made a really interesting discovery but a lot of work remains to turn this into a viable commercial process.”

Ref: energyboom.com
.

Share Recommend | Keep | Reply | Mark as Last Read
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.